Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHDN 2022 | Tackling cognitive impairment in Huntington’s disease: a significant unmet need

Aaron Koenig, MD, Sage Therapeutics, Cambridge, MA, shares his thoughts on the importance of targeting cognitive impairment in patients with Huntington’s disease (HD). Cognitive decline is often one of the earliest signs of HD and can have a significant impact on an individual’s independence and quality of life. Patients can face memory loss, executive dysfunction, and impairments in attention, verbal fluency, and psychomotor speed. Sage Therapeutics are working to develop an NMDA receptor positive allosteric modulator for the treatment of cognitive impairment in HD, an area where there has been little investigation to date. They believe that improving cognitive function would have meaningful effects for patients and their families and remains an area of significant unmet medical need. This interview took place during the European Huntington’s Disease Network 2022 Plenary Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


•Aaron Koenig is an employee of Sage Therapeutics, Inc., and may hold stock and/or stock options.
•The PERSPECTIVE Program is sponsored by Sage Therapeutics, Inc.
•SAGE‐718 is an investigational drug and is not approved by the US Food and Drug Administration or any other regulatory agency as safe and effective for any use.